Gene · 3568
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Genetically inducible coordinators of cytokine signaling pathways for interrogating T cell motility. | bioRxiv | 2026 | 42818027 | PubTator, text mining | PubMed |
Efficacy and Safety of Biologic Therapies Targeting Type 2 and Epithelial-Alarmin Pathways in Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | Cureus | 2026 | 42802784 | PubTator, text mining | PubMed |
| IL-5/IL-5R blockade enables safe non-steroidal anti-inflammatory agent reintroduction in non-steroidal anti-inflammatory exacerbated respiratory disease. | Front Immunol | 2026 | 42755689 | PubTator, text mining | PubMed |
| Benralizumab in Severe Eosinophilic Asthma: Toward Disease Control and Evolving Treatment Paradigms. | J Inflamm Res | 2026 | 42741441 | PubTator, text mining | PubMed |
| Treatment patterns and disease burden of hypereosinophilic syndrome (HES) in the United States: A real-world observational, retrospective cohort study. | World Allergy Organ J | 2026 | 42733636 | PubTator, text mining | PubMed |
| IL-5 biology and eosinophil regulation: Advances, resistance pathways and future directions. | Respir Med | 2026 | 42674274 | PubTator, text mining | PubMed |
| Sequential autoimmune and neoplastic manifestations during long-term benralizumab therapy for severe eosinophilic asthma: A descriptive case report. | Respir Med Case Rep | 2026 | 42633250 | PubTator, text mining | PubMed |
| Integrative Omics of Eosinophils in Asthma and COPD: Deciphering Molecular Signatures for Targeted Therapy. | Mol Diagn Ther | 2026 | 42631787 | PubTator, text mining | PubMed |
| Patient Journey, Treatment Patterns, and Disease Burden of Patients With Idiopathic Hypereosinophilic Syndrome. | EJHaem | 2026 | 42614285 | PubTator, text mining | PubMed |
| Microbiome-driven precision medicine in asthma: Roles of targeted therapies and artificial intelligence. | J Asthma | 2026 | 42613688 | PubTator, text mining | PubMed |
| Eosinophilic cystitis refractory to multiple treatments with good response to benralizumab: case report. | Front Allergy | 2026 | 42609263 | PubTator, text mining | PubMed |
| A four-year journey towards clinical remission and background therapies optimization with benralizumab: A retrospective analysis. | World Allergy Organ J | 2026 | 42571238 | PubTator, text mining | PubMed |
| Comparable 1-year effectiveness of tezepelumab and dupilumab after anti-IL-5/IL-5Rα biologic failure in severe asthma. | Eur J Intern Med | 2026 | 42570933 | PubTator, text mining | PubMed |
| Beyond type 2 inflammation: An innate-myeloid axis is linked to recurrence of chronic rhinosinusitis with nasal polyps. | J Allergy Clin Immunol | 2026 | 42567484 | PubTator, text mining | PubMed |
| IL-5Rα-Mediated Signaling in Eosinophils May Contribute to the Epithelial-Mesenchymal Transition in Eosinophilic Chronic Rhinosinusitis With Nasal Polyps. | J Rhinol | 2026 | 42548224 | PubTator, text mining | PubMed |
| Real-world disease burden, patient journey and treatment patterns in eosinophilic granulomatosis with polyangiitis in Europe and the USA. | EULAR Rheumatol Open | 2026 | 42540107 | PubTator, text mining | PubMed |
| Choosing and switching biologics for patients with severe asthma: Real-world data from the German Asthma Net (GAN). | Allergol Select | 2026 | 42524051 | PubTator, text mining | PubMed |
| Eosinophil IL-5Rα/JAK2/STAT5 Signaling Contributes to Epithelial-Mesenchymal Transition in Eosinophilic Chronic Rhinosinusitis with Nasal Polyps. | Medicina (Kaunas) | 2026 | 42512902 | PubTator, text mining | PubMed |
| Monoclonal Antibodies Directed Against IL-5 in the Treatment of Pediatric Asthma. | Cells | 2026 | 42505356 | PubTator, text mining | PubMed |
| Clinical and molecular correlates of digitally quantified anthracosis in lung tissue slides: utility of an automated quantitative workflow. | J Pathol Clin Res | 2026 | 42473194 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3568/papers